← Back to headlines
Cytokinetics Hits 52-Week High as Revenues Soar
Cytokinetics (CYTK) has reached a 52-week high in its stock price, driven by a dramatic increase in revenues, soaring over 1,000%.
6 May, 01:41 — 6 May, 01:41
Sources
Showing 1 of 1 sources
